Literature DB >> 26305423

NT-proBNP on Cobas h 232 in point-of-care testing: Performance in the primary health care versus in the hospital laboratory.

Charlotte Gils1, Ramshanker Ramanathan, Torben Breindahl, Mette Brokner, Anne L Christiansen, Øyvin Eng, Ida J Hammer, Catherine B Herrera, Aina Jansen, Eva C Langsjøen, Elisabeth S Løkkebo, Toril Osestad, Anne D Schrøder, Lisa Walther.   

Abstract

BACKGROUND: NT-proBNP may be useful for ruling out heart failure in primary health care. In this study we examined the analytical quality of NT-proBNP in primary health care on the Cobas h 232 point-of-care instrument compared with measurements performed in a hospital laboratory.
MATERIALS AND METHODS: Blood samples requested for NT-proBNP were collected in primary health care (n = 95) and in a hospital laboratory (n = 107). NT-proBNP was measured on-site on Cobas h 232 instruments both in primary health care centres and at the hospital laboratory and all samples were also analyzed with a comparison method at the hospital. Precision, trueness, accuracy, and lot-variation were determined at different concentration levels and evaluated according to acceptance criteria. Furthermore user-friendliness was assessed by questionnaires.
RESULTS: For Cobas h 232 repeatability CV was 8.5-10.7% in the hospital setting and 5.3-10.0% in the primary health care and within the analytical quality specifications, but higher than with the comparison method (< 4%). NT-proBNP results obtained in primary health care were significantly higher than by the hospital comparison method (bias ranged from 14.3-23.7%), whereas there was no significant bias when Cobas h 232 was used in the hospital setting (bias ranged from - 4.9 to 7.0%). User-friendliness of Cobas h 232 was overall acceptable.
CONCLUSION: Cobas h 232 point-of-care instrument for measurement of NT-proBNP performed satisfactorily with regard to precision, user-friendliness, and lot-variation. A decrease in NT-proBNP levels observed in samples transported to a central laboratory needs further attention and investigation.

Entities:  

Keywords:  Natriuretic peptide; biological markers; heart disease; point-of-care systems; validation studies

Mesh:

Substances:

Year:  2015        PMID: 26305423     DOI: 10.3109/00365513.2015.1066846

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

Review 1.  Gold Nanoparticles for Diagnostics: Advances towards Points of Care.

Authors:  Mílton Cordeiro; Fábio Ferreira Carlos; Pedro Pedrosa; António Lopez; Pedro Viana Baptista
Journal:  Diagnostics (Basel)       Date:  2016-11-22

2.  Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study.

Authors:  Christoffer Bugge; Erik Magnus Sether; Andreas Pahle; Sigrun Halvorsen; Ivar Sonbo Kristiansen
Journal:  BJGP Open       Date:  2018-07-25

3.  Heart failure prevalence in the general population: SOBOTA-HF study rationale and design.

Authors:  Mitja Lainscak; Daniel Omersa; Natasa Sedlar; Stefan D Anker; Jerneja Farkas
Journal:  ESC Heart Fail       Date:  2019-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.